Use of gabapentin in the treatment of childhood reflex sympathetic dystrophy.

Abstract

Reflex sympathetic dystrophy, a painful syndrome involving an extremity after trauma or injury, is increasingly reported in the pediatric population. Although no clear pathophysiologic mechanism for this disorder has been identified, the role of central serotonin activity seems important. Gabapentin, a new antiepileptic medication, has been demonstrated to be effective in adults with reflex sympathetic dystrophy. The first reported case of a child with a diagnosis of reflex sympathetic dystrophy who was treated successfully with gabapentin is presented.

• Authors: D S Wheeler, K K Vaux, D A Tam
• Journal: Pediatric neurology (Pediatr Neurol) Vol. 22 Issue 3 Pg. 220-1 (Mar 2000) ISSN: 0887-8994 [Print] United States
• PMID: 10734253 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Acetates
• Amines
• Cyclohexanecarboxylic Acids
• Excitatory Amino Acid Antagonists
• gamma-Aminobutyric Acid
• Gabapentin

Topics

• Acetates (administration & dosage, therapeutic use)
• Amines
• Child
• Cyclohexanecarboxylic Acids
• Dose-Response Relationship, Drug
• Excitatory Amino Acid Antagonists (administration & dosage, therapeutic use)
• Female
• Gabapentin
• Humans
• Leg (surgery)
• Recurrence
• Reflex Sympathetic Dystrophy (drug therapy, etiology)
• Treatment Outcome
• gamma-Aminobutyric Acid